Skip to content

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
- Overview
- Pipeline
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
- Overview
- Pipeline
Contact

NASH

A baseline metabolomic signature predicts liver fat (MRI-PDFF) response for denifanstat, a first-in-class, fatty acid synthase (FASN) inhibitor: analysis in FASCINATE-1 and FASCINATE-2 clinical studies

By Graviton / 11/2022

AASLD The Liver Meeting

Serum proteomic profiling reveals that the fatty acid synthase (FASN) inhibitor denifanstat provides metabolic benefits via increasing fibroblast growth factor 19 (FGF19) and decreasing 3-hydroxy-3-methylglutaryl-coa synthase 1 (HMGCS1) in NASH patients

By Graviton / 11/2022

AASLD The Liver Meeting

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

By Graviton / 09/2022

Scientific Reports

A baseline signature of metabolites involving the gut-liver axis predicts MRI-PDFF response to FASN inhibitor TVB-2640 in NASH patients: results from the FASCINATE-1 study

By Graviton / 06/2022

EASL International Liver Congress

NASH, PUBLICATIONS

Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640: efficacy, safety and biomarker results from a global phase 2 randomized pbo-controlled NASH trial, FASCINATE-1

By Graviton / 05/2022

Digestive Disease Week

Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640 demonstrates robust clinical efficacy and safety in a global phase 2 randomized placebo-controlled NASH trial (FASCINATE-1)

By Graviton / 01/2022

NASH-TAG

TVB-2640, a novel, first-in-class, fatty acid synthase (FASN) inhibitor: biomarker and metabolomic correlations with clinical MRI-PDFF response

By Graviton / 11/2021

NASH Summit

Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640 demonstrates robust clinical efficacy and safety in a global phase 2 randomized placebo-controlled NASH trial (FASCINATE-1) conducted in the U.S. and China

By Graviton / 11/2021

AASLD The Liver Meeting

Translation of FASN Inhibitor TVB-2640 from Preclinical MOA to Clinical POC in NASH

By Graviton / 09/2021

NASH and Fibrosis Conference

TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial

By Graviton / 07/2021

Gastroenterology

Post pagination

← Previous 1 2 3 4 Next →

Site map

About
Science
Investors
Programs
Contact

About
Science
Investors
Programs
Contact

Contact us

Business Development
bd@sagimet.com

Investors
ir@sagimet.com

Media
media@sagimet.com

Human Resources
hr@sagimet.com

© 2024 Sagimet Biosciences. All Rights Reserved. Terms of Use Agreement | Privacy Policy | Clinical Trial Privacy Notice

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
- Overview
- Pipeline
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
- Overview
- Pipeline
Contact

Scroll to Top